Business Daily Media

Business Marketing

.

First Subject Enrolled in Phase 1 Study of MRX-5

  • Written by PR Newswire

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.

MRX-5 is a new type of benzodiazepine antibiotic used to treat infections caused by NTMs (non-tuberculous mycobacteria). Non-tuberculosis mycobacteria refers to a large class of bacteria, excluding Mycobacteria tuberculosis, which causes chronic lung infections and results in lung damage and high mortality rates.  At least 250,000 people worldwide are actively being treated for NTM infections and incidence is increasing globally.

To date, more than 190 NTM species and 14 subspecies have been identified, with the most common pathogenic NTMs including the Mycobacterium abscess and the Mycobacterium avium complex. NTM infections require 12-24 months of antibiotic therapy taken multiple times per day.  Current treatments result in a high number of adverse reactions, inadequate clinical resolution, poor compliance and poor prognosis. Treatment of NTM patients, especially resistant patients, has significant unmet needs. New antibiotics which have greater efficacy, fewer adverse events and better patient compliance are urgently needed.

MicuRx is developing MRX-5 for treatment of refractory NTM infections.  Pre-clinical studies have shown that MRX-5 has good antibacterial activity for most common NTM bacteria and good safety in animal toxicology studies.

This Phase 1 study, the first human clinical trial of MRX-5, is conducted at the Nucleus Network Research Centre in Australia to assess the safety, tolerance, pharmacodynamic characteristics and food effects of oral MRX-5 in healthy subjects. The trial has previously been approved by the Australian Ethics Commission for Human Research (HREC) and has completed the clinical trial filing at the Therapeutic Goods Administration (TGA).  Completion is expected in 2024.

MicuRx is committed to advancing our pipeline products to serve the infectious disease and critical care markets where more therapeutic options are needed to address unmet medical needs.

Read more https://www.prnasia.com/story/archive/4273363_CN73363_0

Tips for Your First Move Into Your Commercial Property

Investing in a commercial property is a bold decision, especially when looking to scale up your business. However, a commercial building differs f...

Property

Help needed for SMEs to compete for government contracts

The Australian Small Business and Family Enterprise Ombudsman Kate Carnell said small businesses will play a critical role in the post COVID eco...

Business Training

Tips for Keeping Your Business OSHA Compliant

As a business owner, you are legally and morally responsible for your employee's safety and wellness. OSHA sets standards and regulations that bus...

Business Training

3 Essential SEO Services To Help Grow Your Business

Did you know that 44% of businesses have an SEO strategy? SEO remains a powerful SEO strategy for everyone, from startups to businesses big and s...

Business Training

ClickFunnels Review: The Best Way to Create a Sales Funnel

The Ultimate Guide to ClickFunnels: What is it and How to Use it Whether you run a small business or are in charge of marketing for a large cor...

Business Training

Dr Warren Harmer: Pugs: What they can teach us about sales

I have 2 of the cutest housemates imaginable: pugs. Ernie is a 2 year old fawn with a slightly anxious but very sweet personality. Frank is a 6 mont...

Business Training